References
Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22:886–94.
Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA 2017; 114: 4993–8.
Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci 2017; 18: 6.
Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003; 206:353–6.
Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439–44.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takimoto, R., Honda, T., Kataoka, T.R. et al. DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab. Eur J Dermatol 29, 228–229 (2019). https://doi.org/10.1684/ejd.2019.3522
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3522